Estimated lifetime Cardiovascular, Kidney, and mortality benefits of combination treatment with SGLT2 Inhibitors, GLP-1 receptor Agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria
A Mayo Clinic study in The Lancet [1] (2025) followed 400 postmenopausal women on tirzepatide for 12+ months: HRT + tirzepatide: 17% total body weight loss Tirzepatide alone: 14% or 35% less 45% of HRT users achieved 20% weight loss vs
The fix: weigh weekly under consistent conditions (morning, after bathroom, before food)
In the full episode, I cover: -The state of evidence for alleged geroprotective effects of GLP-1 receptor agonists, SGLT2 inhibitors, methylene blue, and telomere-lengthening supplements -Risks and benefits associated with low-dose aspirin for cardiovascular disease (CVD) prevention -Evidence regarding optimal protein intake for maximizing muscle mass, and whether follistatin gene therapy might have promise for further increasing muscle gains -How to apply evidence-based reasoning to separate science from speculation in longevity research -More This AMA episode (Ep
Successful client representation in West Virginia Successful legal representation is a result of years of study and years of practice in and out of the courtroom